Skip to content
DraconiticResearch
Search Sources API
197,761 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY-NC-NDResearch and practice in thrombosis and haemostasis

Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations

  • Tzu-Fei Wang1
  • Melissa F. Glasner2
  • Rasha Al-Lamee3
  • María Cecilia Bahit4
  • Jonathan M. Coutinho5
  • David Gailani6
  • S. Claiborne Johnston7
  • Carolyn S.P. Lam8
  • Wolfgang C. Winkelmayer9
  • Jeffrey I. Weitz10
10 affiliations
  1. 1Division of Hematology, University of Ottawa; The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
  2. 2The France Foundation, Old Lyme, Connecticut, USA
  3. 3Imperial College Healthcare NHS Trust and Imperial College London, London, United Kingdom
  4. 4Department INECO Neurociencias, World Stroke Organization Heart and Brain Task Force, Rosario, Argentina
  5. 5Department of Neurology, Amsterdam University Medical Center, Amsterdam, The Netherlands
  6. 6Vanderbilt University Medical Center, Nashville, Tennessee, USA
  7. 7Department of Neurology, University of California, San Francisco, California, USA
  8. 8National Heart Centre Singapore; Duke-National University of Singapore, Singapore
  9. 9Baylor College of Medicine; Selzman Institute for Kidney Health, Houston, Texas, USA
  10. 10Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
Read full textPDFCite

Related

  1. Anticoagulation in advanced renal failure: do factor XI/XIa inhibitors represent the long-awaited shift?
    Domenico Prisco, Edoardo Biancalana, Danilo Malandrino +1
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textHuman geneticsDOAJ
  2. Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study
    Sergei Boichuk, Tatyana Gessel, Pavel Dunaev +5
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Plant-Derived Dipeptidyl Peptidase-4 Inhibitors in Cardiometabolic Disorders: A Critical Review of Natural Scaffolds and Experimental Evidence
    Kuanysh Zhapar, Diana Samatkyzy, Diana Valishayeva +3
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Long-Term Cardiovascular, Thromboembolic, and Malignancy Safety of Janus Kinase (JAK) Inhibitors in Dermatologic and Rheumatologic Populations: A Narrative Comparative Review.
    Shakira Bou Rolon, Andrea N Ortiz Echevarria, Monica Burgos Claudio +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. The Role of Telomerase in Cellular Stress Response—Therapeutic Potential of Telomerase Inhibitors
    Sandra Pawlak, Magdalena Kostrzewa, Natalia Lisiak +1
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{wang2026evaluating,
  title = {{Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations}},
  author = {Tzu-Fei Wang and Melissa F. Glasner and Rasha Al-Lamee and María Cecilia Bahit and Jonathan M. Coutinho and David Gailani and S. Claiborne Johnston and Carolyn S.P. Lam and Wolfgang C. Winkelmayer and Jeffrey I. Weitz},
  journal = {Research and practice in thrombosis and haemostasis},
  year = {2026},
  month = jul,
  url = {https://europepmc.org/article/PMC/PMC13700376},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations
AU  - Tzu-Fei Wang
AU  - Melissa F. Glasner
AU  - Rasha Al-Lamee
AU  - María Cecilia Bahit
AU  - Jonathan M. Coutinho
AU  - David Gailani
AU  - S. Claiborne Johnston
AU  - Carolyn S.P. Lam
AU  - Wolfgang C. Winkelmayer
AU  - Jeffrey I. Weitz
PY  - 2026
DA  - 2026/07/31
JO  - Research and practice in thrombosis and haemostasis
UR  - https://europepmc.org/article/PMC/PMC13700376
SN  - 2475-0379
ER  -